<DOC>
	<DOCNO>NCT01272440</DOCNO>
	<brief_summary>Asparaginase important drug treatment childhood leukaemia . The aim project study pharmacokinetics , pharmacodynamics antibody development hypersensitivity reaction prolong PEG-asparaginase treatment . Study part 1 ) Asparaginase pharmacokinetics pharmacodynamics prolong PEG-asparaginase treatment : A NOPHO ALL-2008 study Study part 2 ) Asparagine depletion cerebrospinal fluid : A NOPHO ALL-2008 study Study part 3 ) A characterization PEG-asparaginase hypersensitivity child treat accord NOPHO ALL 2008 protocol Perspectives : New knowledge PEG-asparaginase treatment regard dosing , dose interval , adverse effect EFS , may lead improved future therapy Patients : Children diagnose acute lymphoblastic leukaemia Nordic Countries</brief_summary>
	<brief_title>A Drug Monitoring Study PEG-asparaginase Treatment Children Diagnosed Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Children age 1 18 year old , diagnose ALL treat accord NOPHOALL 2008 protocol accept participate study Children attend NOPHOALL 2008 protocol receive standard treatment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>PEG-asparaginase</keyword>
	<keyword>child</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antibody</keyword>
	<keyword>acute lymphoblastic leukaemia</keyword>
	<keyword>adverse effect</keyword>
</DOC>